Atezolizumab

Atezolizumab, obinutuzumab and venetoclax combined produced a durable response in relapsed/refractory diffuse large B-cell lymphoma but presented best in low tumor burden cases, according to a poster presented at ASCO20 Virtual Scientific Sessions.

Atezolizumab plus platinum-based chemotherapy prolonged PFS as first-line therapy for patients with metastatic urothelial carcinoma, according to results of the randomized phase 3 IMvigor130 trial published in The Lancet.

The treatment landscape for relapsed and refractory small cell lung cancer is an area ripe for investigation.

The FDA approved four regimens for non-small cell lung cancer since mid-May.

In this video, Julia K. Rotow, MD, medical oncologist at Dana-Farber Cancer Institute, shared her thoughts on data from the CITYSCAPE trial presented during the ASCO20 Virtual Scientific Program.

The addition of atezolizumab to chemotherapy improved pathologic complete response among patients with early triple-negative breast cancer, according to the agent’s manufacturer.

In this video, Vivek Subbiah, MD, associate professor at The University of Texas MD Anderson Cancer Center, discussed results from KEYNOTE-604.

The FDA approved atezolizumab in combination with bevacizumab for the treatment of patients with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy.

Adjuvant atezolizumab failed to extend DFS compared with observation for patients with high-risk muscle-invasive urothelial carcinoma, according to randomized phase 3 study results presented during the ASCO20 Virtual Scientific Program.

Thomas A. Abrams, MD, senior physician at Dana-Farber Cancer Institute and assistant professor of medicine at Harvard Medical School, spoke with Healio about treatment options for patients with hepatocellular carcinoma. He discusses first-line treatment, guidance on aspirin use and important, recent FDA approvals.